Exploring Therapeutic Mechanisms to Improve Organ Function in CVRM Diseases
Published: 02 October 2024
-
Views:
89
-
Likes:
7
-
Views:
89
-
Likes:
7
-
2m 52sPart 1 Chair Welcome and Introduction Hiddo Lambers Heerspink, Carel le Roux, Ildiko Lingvay
-
13m 55sPart 2 Beneficial Effects of GLP-1 RAs: Weight Loss Mediated or Direct Action? Hiddo Lambers Heerspink, Carel le Roux, Ildiko Lingvay
Overview
First presented at EASD 2024, this on-demand programme sees Prof Hiddo Heerspink lead a distinguished faculty comprising of Prof Carel le Roux and Prof Ildiko Lingvay.
This symposium features vital discussions on the effects of GLP-1–weight loss mediated versus direct action and the mechanistic synergies of the actions of SGLT2 inhibitors and GLP-1 agonists on organ function.
Date of Prep: September 2024
Z4-69899
Key Learning Objectives
- Understand the different mechanisms by which GLP-1 agonists achieve their beneficial effects including weight loss, glycaemic control and direct receptor activation
- Appreciate the mechanisms by which GLP-1 agonists and SGLT2 inhibitors protect major organs
- Understand how the mechanistic synergies of combination therapy with a GLP-1 receptor agonist plus an SGLT2 inhibitor may improve treatment outcomes
Target Audience
- General Cardiologists
- Primary Care Physicians
- Diabetologists
- Endocrinologists
More from this programme
Part 1
Chair Welcome and Introduction
| 1 session | |
| Chair Welcome and Introduction | Watch now |
Part 2
Beneficial Effects of GLP-1 RAs: Weight Loss Mediated or Direct Action?
Part 3
Mechanistic Synergies of the Actions of SGLT2 Inhibitors and GLP-1 RAs on Heart and Liver
Part 4
Mechanistic Synergies of the Actions of SGLT2 Inhibitors and GLP-1 RAs on Kidney Protection
Part 5
How Can We Utilise the Mechanistic Insights to Further Improve Treatments of Patients?
Faculty Biographies
Hiddo Heerspink
Clinical Pharmacologist
Prof Hiddo Heerspink’s is a Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands. he also serves as a Visiting Professor at the University of New South Wales in Sydney, Australia. Prof Heerspink's research interests include treatment strategies and therapeutic approaches for the treatment of renal and cardiovascular disease in patients with diabetes.
Carel le Roux
Head of Pathology
Prof Carel le Roux is Head of Pathology at University College Dublin, Dublin, IE.
He graduated from medical school in Pretoria South Africa, completed his Senior House Officer training at Barts and The London Hospital, his SpR training in metabolic medicine at the Hammersmith Hospitals and his PhD at Imperial College London.
Working within the Diabetes Complications Research Centre and the Section of Surgery and Surgical Specialities, the focus of Prof le Roux's research is primarily concerned with increased mortality and morbidity associated with obesity and diabetes.
Ildiko Lingvay
Endocrinologist
Dr Ildiko Lingvay is an Endocrinologist and Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Texas, US.
Dr Lingvay earned her medical degree with honors at the University of Medicine and Pharmacy in Bucharest.
She specialises in clinical research in the fields of obesity, diabetes, and metabolic complications. Her research interests include metabolic syndrome, obesity, and diabetes mellitus.
Comments